CLARITY MEDICAL GROUP HOLDING LIMITED
清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1406)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Clarity Medical Group Holding Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that Mr. Cao Jian ("**Mr. Cao**") has been appointed as an executive Director ("**ED**") by the Board, with effect from 1 October 2026.

Mr. Cao will enter into a service agreement with the Company for a term of 3 years commencing from 1 October 2026, which may be terminated by not less than three calendar months' notice in writing or payment in lieu of notice served by either party on the other. Mr. Cao will be subject to re-election at the next annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once every three years in accordance with the articles of association of the Company and the Listing Rules. Mr. Cao will not receive any director's fee for his appointment as an executive Director, but is entitled to a salary in his capacity as the Vice President of Finance of the Group, as recommended by the remuneration committee of the Company and determined by the Board with reference to his duties, responsibilities, experience, and prevailing market conditions.

The biographical details of Mr. Cao required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out below:

Mr. Cao, aged 37, has over 14 years of experience in auditing, financial advisory and corporate financial management. He is currently the Vice President of Finance of the Group.

Mr. Cao obtained a bachelor's degree in Accounting from Sun Yat-sen University in 2012. He is a member of the Chinese Institute of Certified Public Accountants.

From October 2012 to October 2016, Mr. Cao worked at PricewaterhouseCoopers, where he served as a Senior Associate in Assurance. From October 2016 to June 2024, he worked at KPMG, where he last served as an Associate Director in Deal Advisory. From July 2024 to March 2025, he served as the Director of the Finance Centre of Excellence of DeRucci Healthy Sleep Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 001323).

Mr. Cao joined the Group in April 2025 and has served as the Vice President of Finance of the Group since then.

To the best of the Directors' information, knowledge and belief, having made all reasonable enquiries, save as disclosed above, Mr. Cao (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (ii) does not have any other major appointments and professional qualifications; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company.

As at the date of this announcement and save as disclosed above, Mr. Cao (i) does not have, and is not deemed to have any interests or short positions in any shares or underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) does not have any other positions held within the Company or other members of the Group.

Save as disclosed above, and as far as the Board is aware, there is no other information that needs to be disclosed in accordance with Rule 13.51(2) of the Listing Rules concerning the appointment of Mr. Cao, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to extend a warm welcome to Mr. Cao on joining the Board.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
JIANG Bo
Executive Director and Chief Executive Officer

Hong Kong, 23 September 2026

As at the date of this announcement, the Board comprises Mr. JIANG Bo and Mr. Cao Jian as executive Directors, Mr. CHEN Jiarong, Professor WANG Qinmei and Mr. SUN Peng as non-executive Directors, and Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian and Mr. XU Anliang as independent non-executive Directors.